Antimicrobial activity of Manuka honey against antibiotic resistant strains of the cell wall free bacteria ureaplasma parvum

 and Ureaplasma urealyticum by Hillitt, K. L. et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/97184/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Hillitt, K. L., Jenkins, R. E., Spiller, Owen Bradley and Beeton, M. L. 2017. Antimicrobial activity
of Manuka honey against antibiotic resistant strains of the cell wall free bacteria ureaplasma parvum
and Ureaplasma urealyticum. Letters In Applied Microbiology 64 (3) , pp. 198-202.
10.1111/lam.12707 file 
Publishers page: http://dx.doi.org/10.1111/lam.12707 <http://dx.doi.org/10.1111/lam.12707>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
1 
 
Article title: Antimicrobial activity of Manuka honey against antibiotic resistant strains of the 1 
cell wall free bacteria Ureaplasma parvum and Ureaplasma urealyticum. 2 
 3 
Hillitt K. L.1, Jenkins, R. E.1, Spiller O. B2 and Beeton M. L.1* 4 
 5 
1Cardiff School of Health Sciences, Cardiff Metropolitan University, Cardiff, UK; 2School of 6 
Medicine, Cardiff University, University Hospital of Wales, Cardiff, UK. 7 
 8 
*Corresponding author: Dr Michael L Beeton; Telephone: 02920 205557; e-mail: 9 
mbeeton@cardiffmet.ac.uk 10 
 11 
Running title: Activity of honey against Ureaplasma 12 
 13 
  14 
2 
 
SigŶifiĐaŶĐe aŶd iŵpaĐt of the study 15 
Manuka honey is known to have a broad spectrum of antimicrobial activity, with the 16 
bacterial cell wall being suggested as a predominant site of action.  This study has 17 
demonstrated that Manuka honey has activity against Ureaplasma spp., a genus of cell-wall 18 
free bacteria which are intrinsically resistant to many available antibiotics making treatment 19 
inherently difficult.  This is the first report of the antimicrobial activity of Manuka honey 20 
against a bacterial pathogen, in the absence of a cell well and opens scope for the use of 21 
components of Manuka honey as a therapeutic among Ureaplasma infections. 22 
 23 
AďstraĐt 24 
The susceptibility of the cell-wall free bacterial pathogens Ureaplasma spp. to Manuka 25 
honey was examined.   The minimum inhibitory concentration (MIC) of Manuka honey for 26 
four Ureaplasma urealyticum and four Ureaplasma parvum isolates was determined.  27 
Sensitivity to honey was also compared to clinical isolates with resistance to tetracycline, 28 
macrolide and fluoroquinolone antibiotics.  Finally step-wise resistance training was utilised 29 
in an attempt to induce increased tolerance to honey.  The MIC was dependent on the initial 30 
bacterial load with 7.5 % and 18.0 % w/v honey required to inhibit U. urealyticum at 1 and 31 
106 colour changing units (CCU), respectively, and 4.8 % and 15.3 % w/v required to inhibit 32 
U. parvum at 1 and 106 CCU, respectively. MIC values were consistently lower for U. parvum 33 
compared with U. urealyticum.  Antimicrobial activity was seen against tetracycline 34 
resistant, erythromycin resistant and ciprofloxacin resistant isolates at 105 CCU.  No 35 
resistance to honey was observed with fifty consecutive challenges at increasing 36 
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concentrations of honey.  This is the first report of the antimicrobial activity of Manuka 37 
honey against a cell-wall free bacterial pathogen.  The antimicrobial activity was retained 38 
against antibiotic resistant strains and it was not possible to generate resistant mutants. 39 
 40 
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IŶtroduĐtioŶ 44 
Ureaplasma spp. are a genus of bacteria of clinical relevance strongly linked with preterm 45 
birth and subsequent development of neonatal complications such as bronchopulmonary 46 
dysplasia, intraventricular haemorrhaging and necrotising enterocolitis (Viscardi, 2014).  47 
Additionally these pathogens are becoming recognised in sexual health (Zhang et al., 2014, 48 
Ondondo et al., 2010) and immune compromised transplant patients (Bharat et al., 2015).  49 
The unique physiology of these organisms results in high levels of intrinsic resistance to 50 
many clinically available antibiotics.  For example, the absence of a peptidoglycan cell wall 51 
renders these organisms resistant to all beta-lactam and glycopeptide antibiotics.  Only a 52 
limited number of antimicrobial classes are available for treatment including the macrolides, 53 
tetracyclines, fluoroquinolones and chloramphenicols.  With respect to infection during 54 
pregnancy and among preterm neonates these options are further limited due to host 55 
toxicity issues.  Tetracyclines are associated with deposition in growing teeth and bones 56 
whereas systemic administration of chloramphenicol is associated with ͞Grey baby͟ 57 
syndrome. Further complications arise as a result of isolates harbouring acquired resistance 58 
to the limited number of available antibiotics, with exception to chloramphenicol (Beeton et 59 
al., 2015, Beeton et al., 2009b).  For these reasons alternatives are urgently required.   60 
 61 
Manuka honey has been shown to be a promising natural product with potent antimicrobial 62 
activity against pathogens such as Staphylococcus aureus and Pseudomonas 63 
aeruginosa.(Jenkins et al., 2011, Jenkins et al., 2012)  Unlike many traditional antibiotics 64 
which have a single site of action, honey has been suggested to have multiple antimicrobial 65 
components such as hydrogen peroxide, high levels of sugars, and methylglyoxal (Maddocks 66 
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and Jenkins, 2013).  Due to the multifaceted antimicrobial nature of this product it has been 67 
difficult to generate resistance in vitro (Cooper et al., 2010). 68 
 69 
Here we present data demonstrating the first report of antimicrobial activity of Manuka 70 
honey against a cell-wall free bacterial pathogen.  Additionally, we show no increase in 71 
susceptibility for clinical isolates characterised to have known mechanisms of antibiotic 72 
resistance, nor could resistance to honey be induced with repeated challenge of strains with 73 
concentrations of Manuka honey just below the MIC with classic in vitro step-wise training. 74 
 75 
Results aŶd disĐussioŶ 76 
A total of eight antibiotic susceptible Ureaplasma strains were initially examined for 77 
baseline susceptibility to Manuka honey using the modified broth microdilution method. For 78 
both U. urealyticum and U. parvum the percentage of Manuka honey required to yield 79 
inhibition increased in relation to the increase in initial inoculum (from 7.5% at 1 CCU to 80 
18.0% at 106 CCU for U. urealyticum and 4.8% at 1 CCU to 15.3% at 106 for U. parvum) 81 
(Table 1).  At the Clinical & Laboratory Standards Institute (CLSI) recommended inoculum of 82 
104 - 105 for testing antimicrobials against Ureaplasma spp., the mean MIC for U. 83 
urealyticum was higher than that of U. parvum (13.5 vs 12.7 at 104 and 16.7 vs 15.8 at 105), 84 
but this difference was not statistically significant (p = 0.49). Following the establishment of 85 
baseline MIC values for Manuka honey against both U. urealyticum and U. parvum, the 86 
activity was then assessed against a small representative collection of antibiotic resistant 87 
strains.  No increase in MIC was noted for any resistant strain at the recommended 104 or 88 
105 CCU relative to the matched inoculum for each respective antibiotic susceptible species 89 
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(Table 2).  The antibiotic susceptible strain HPA5 was serially passaged in sub-inhibitory 90 
concentrations of Manuka honey in an attempt to generate honey resistant isolates.  After 91 
50 serial passages no elevation in Manuka honey MIC was noted (data not shown).  92 
 93 
The purpose of this study was to evaluate the antimicrobial activity of Manuka honey 94 
against a panel of clinical and laboratory strains of Ureaplasma spp.  From this we report the 95 
first example of antimicrobial activity of Manuka honey against a cell-wall free bacterial 96 
pathogen as well as retention of activity against clinically relevant antibiotic resistant 97 
strains.  Data available to date on the antimicrobial activity of Manuka honey has been 98 
generated in respect to typical bacterial pathogens such as S. aureus and P. aeruginosa 99 
(Jenkins et al., 2011, Camplin and Maddocks, 2014).  It has been suggested that one of the 100 
primary mechanisms of action of Manuka honey is targeting the cell wall murein hydrolase 101 
therefore disrupting cellular division (Jenkins et al., 2011).   As a result of reductive 102 
evolution ureaplasmas have lost the biosynthetic capabilities to synthesise the 103 
peptidoglycan cell wall.  From the data presented here we can speculate there are 104 
additional cellular targets other than the cell wall which leads to the antimicrobial activity, 105 
which reflects that previously suggested by Jenkins et al., (Jenkins et al., 2014).  In addition 106 
non-specific effects as a result of osmotic imbalances may have contributed to the 107 
antimicrobial activity. The MIC values for both Ureaplasma spp. were lower than those 108 
reported for the ATCC 9027 strain of P. aeruginosa (25.6 % w/v), yet comparable to a clinical 109 
P. aeruginosa isolate (15.3 % w/v),(Camplin and Maddocks, 2014) but were much higher 110 
than those previously reported for S. aureus <6 % w/v (Jenkins et al., 2012).  These subtle 111 
differences may be due to the sites of action upon the pathogen in question, such as the cell 112 
wall in S. aureus, or differences in the Unique Manuka Factor between batches of honey 113 
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examined.  When examining the MIC values between the Ureaplasma spp. we noted that U. 114 
urealyticum had consistently higher MIC values at the CLSI recommended inoculum of 104 to 115 
105 when compared with U. parvum.  Although this was not a statistically significant 116 
difference, this reflects the observations in species difference seen when examining the 117 
activity of antibiotics against these pathogens (Beeton et al., 2016). Of clinical relevance was 118 
the observation that bacterial load played a substantial role in the MIC for both U. parvum 119 
and U. urealyticum.  Low grade infections would be treatable with much lower 120 
concentrations of honey, where as those with high titres, as seen clinically, would require 121 
much higher concentrations (Beeton et al., 2016).  Antibiotic resistant strains have been 122 
reported for the major classes of antibiotics effective against ureaplasmas, most notably the 123 
macrolides, tetracyclines and fluoroquinolones (Beeton et al., 2009b, Beeton et al., 2015).  124 
For this reason we examined the antimicrobial activity of honey against a panel of antibiotic 125 
resistant clinical isolates.  We observed retention of antimicrobial activity against these 126 
isolates suggesting no cross-resistance from either antibiotic resistance mechanism or the 127 
activity of honey.  This is of significance in the case of preterm neonatal infections where 128 
macrolides are regarded the predominant antibiotic class of choice.   Pereyre et al. 2007, 129 
have previously demonstrated the ease by which ureaplasmas can acquire point mutations 130 
resulting in the development of resistance following exposure to macrolides via step wise 131 
resistance training (Pereyre et al., 2007).  Similarly resistance to fluoroquinolones among 132 
Ureaplasma spp. results from the accumulation of mutations in the quinolone resistance 133 
determining regions (Beeton et al., 2009a).  The data presented here demonstrated that it 134 
was not possible to generate isolates with an increased honey MIC following a similar time 135 
frame in which macrolide resistance was generated (Pereyre et al., 2007).  This is likely due 136 
to the suggested multiple antimicrobial agents present with in Manuka honey (Maddocks 137 
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and Jenkins, 2013).  The inability to generate mutants is in line with previous reports for S. 138 
aureus and P. aeruginosa although a report by Camplin and Maddocks demonstrated an 139 
increase in MIC for P. aeruginosa isolates recovered from honey treated in vitro biofilms 140 
(Cooper et al., 2010, Camplin and Maddocks, 2014).  141 
 142 
In summary we have successfully demonstrated antimicrobial activity of Manuka honey 143 
against a bacterial pathogen with high levels of intrinsic and acquired antibiotic resistance in 144 
the absence of a cell wall.  The mechanisms by which Manuka honey exerts antimicrobial 145 
activity in this atypical bacterial pathogen of increasing clinical significance warrants further 146 
investigation. 147 
 148 
Materials aŶd ŵethods 149 
A total of eight antibiotic susceptible Ureaplasma strains were examined.  These comprised 150 
of four U. urealyticum including two clinical isolates (HPA99 and W11) and two reference 151 
strains (ATCC 27814 SV2 and ATCC 27618 SV8), in addition four U. parvum including two 152 
clinical isolates (HPA2 and HPA5) and two reference strains (ATCC 700970 SV3 and ATCC 153 
27818 SV6).  Representative antibiotic resistant strains ATCC 33175 SV9 (tetracycline 154 
resistant), UHWO10 (erythromycin resistant) and HPA116 (ciprofloxacin resistant) were 155 
included (Beeton et al., 2009b, Beeton et al., 2015).  All Ureaplasma isolates were grown in 156 
Ureaplasma selective media purchased from Mycoplasma Experience (Surrey, UK).  157 
Susceptibility to Activon 100% Medical Grade Manuka honey, purchased from Advancis 158 
Medical (Nottinghamshire, UK), was determined using CLSI M43-A guidelines for 159 
antimicrobial susceptibility testing for human mycoplasmas. In brief, a dilution gradient of 160 
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honey prepared in Ureaplasma Selective Media from 20 % w/v to 0 % w/v (2% increments) 161 
were prepared.  180 µl of each dilution was then added to all wells with in columns of a 96 162 
well microtiter plate. For example 180 µl 20 % w/v honey was added to wells A12 – H12, 180 163 
µl 18 % w/v honey was added to wells A11 – H11.  Finally 20 µl of a logarithmic phase 164 
culture of Ureaplasma was added to the all wells from A1 – A12.  1:10 dilutions from this 165 
were made across the plate from column one though to column eight as a means for 166 
determining the inhibitory activity of the Manuka honey at multiple concentrations of 167 
bacteria.  Plates were sealed with an adhesive sealing film and incubated statically at 37 oC 168 
until all colour change had ceased as determined visually (c.a 48 hours).  Colour changing 169 
units (CCU) were defined by determining the final dilution in which colour change had 170 
occurred, orange to red due to increased pH as a result of urea hydrolysis, therefore giving 171 
one CCU.  From this it was then possible to work back through the dilution gradient to 172 
determine the percentage of honey required to inhibit the growth of Ureaplasma at each 173 
CCU.  The methodology as previously described by Pereyre et al., was used to select for 174 
honey resistant mutants using the antibiotic susceptible strain HPA5 (Pereyre et al., 2007).  175 
Statistical analysis was performed using Minitab version 17.0 to determine the statistical 176 
significance using a one-way ANOVA. 177 
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 Colour Changing Units (CCU) 
1 101 102 103 104 105 106 
U. urealyticum  
ATCC 27814 SV2 4.0 + 3.2 7.0 + 5.5 11.3 + 1.1 11.3 + 1.1 12.7 + 1.1 16.7 + 4.2 16.0 + * 
HPA99 7.3 + 4.2 8.7 + 3.1 9.3 + 2.3 10.7 + 1.2 12.7 + 1.2 17.0 + 4.2 N/A 
W11 8.7 + 4.2 10.0  + 3.5 10.0 + 3.5 12.0 + 3.5 13.3 + 3.1 14.0 + * 20.0 + * 
ATCC 27618 SV8 10.0 + 2.0 12.0 + 2.0 14.0 + 0.0 14.0 + 0.0 15.3 + 2.3 19.0 + 1.4 N/A 
U.u mean 7.5 + 2.6 9.4 + 2.1 11.1 + 2.1 12.0 + 1.4 13.5 + 1.2 16.7 + 2.1 18.0 + 2.8 
U. parvum  
HPA5 2.3 + 1.5 9.3 + 6.4 11.3 + 4.6 12.0 + 3.45 12.7 + 2.3 16.7 + 1.2 20.0 + * 
ATCC 700970 SV3 7.3 + 4.6 10.7 + 1.2 10.7 + 1.2 11.3 + 2.3 12.7 + 2.3 18.0 + * N/A 
ATCC 27818 SV6 2.3 + 1.6 11.3 + 1.1 12.7 + 1.2 12.7 + 1.2 13.3 + 1.2 15.3 + 3.0 12.0 + * 
HPA2 7.3 + 3.0 10.7 + 1.2 11.3 + 1.2 11.3 + 1.1 12.0 + 0.0 13.3 + 2.3 14.0 + 2.8 
U.p mean 4.8 + 2.9 10.5 + 0.8 11.5 + 0.8 11.8 + 0.7 12.7 + 0.5 15.8 + 2.0 15.3 + 4.2 
 240 
Table 1. Antimicrobial activity of Manuka honey against varying inoculum numbers of Ureaplasma urealyticum and 241 
Ureaplasma parvum isolates.  Results represent the mean Manuka honey minimum active dilution (% w/v) as well as standard 242 
deviation (triplicates). ‘*’ indicates only a single replicate was tested. CLSI guidelines recommend a level of 104 – 105 CCU for 243 
reliable antimicrobial susceptibility testing.  N/A = non-applicable. U.u = U. urealyticum. U.p = U. parvum 244 
 245 
 246 
 247 
 248 
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 Colour Changing Units (CCU) 
1 101 102 103 104 105 106 
Ureaplasma spp.  
ATCC 33175 SV9 (Tetr) 6.7 + 5.0 9.3 + 3.0 10.7 + 2.3 10.7 + 2.3 11.3 + 1.2 11.3 + 1.2 12.0 + 2.0 
UHWO10 (Eryr) 7.0 + 5.6 8.0 + 5.3 8.0 + 5.3 8.0 + 5.3 8.7 + 4.2 9.3 + 5.0 10.0 + 5.3 
HPA116 (Cipr) 8.0 + 3.6 9.3 + 4.6 10.0 + 3.5 10.7 + 4.2 11.3 + 4.6 12.0 + 3.5 12.0 + 3.5 
 249 
Table 2. Antimicrobial activity of Manuka honey against varying inoculum numbers of antibiotic resistant Ureaplasma spp.  250 
Results represent the mean Manuka honey minimum active dilution (% w/v) as well as standard deviation (triplicates). ATCC 33175 251 
SV9 (Tetr) represents a tetracycline resistant strain, UHWO10 (Eryr) represents an erythromycin resistant strain and HPA116 (Cipr) 252 
indicates a ciprofloxacin resistant strain.  CLSI guidelines recommend a level of 104 – 105 CCU for reliable antimicrobial 253 
susceptibility testing. 254 
 255 
